Investigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF)
Recruiting
N/A
Interventional Study
Persistent Atrial Fibrillation
Cardiac Arrhythmia
Catheter Ablation
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 85
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 208 (estimated)
- Sponsor
- Barts & The London NHS Trust · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The main aim of the research is to investigate whether patients undergoing pulmonary vein isolation with catheter ablation for persistent atrial fibrillation (AF) will have lower rates of AF recurrence than those treated by DC cardioversion without an ablation procedure.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Ability to give informed consent
* Age 18-85 years
* Persistent AF (atrial fibrillation lasting \> 7days) of total continuous duration \<2 years as documented in medical notes.
* Patients being considered for cardioversion.
Exclusion Criteria:
* Creatinine clearance (eGFR) \…
Contacts